Press Releases

     2017

01/30/2017 Ferring, Enteris to Develop Oral Peptide Therapeutic

01/25/2017 Enteris, KeyBioscience to Develop Solution for Metabolic Disorders

01/23/2017 Enteris, Sanofi to Develop Oral Therapeutic for Type 2 Diabetes

     2016

09/19/2016 Enteris BioPharma’s “Feasibility to Licensing” Partner, Cara Therapeutics, Advances Peptelligence™-Engineered CR845 into Phase 2b Clinical Trial in Chronic Pain

07/13/2016 Enteris BioPharma Initiates Clinical Program for Tobrate (oral tobramycin tablet) in Uncomplicated Urinary Tract Infection

01/19/2016 Enteris BioPharma Enhances Executive Leadership Team to Target Strategic Growth Opportunities

     2015

10/19/2015 Enteris BioPharma’s Formulation Technology Enables Oral Delivery of Tarsa Therapeutics’ TBRIA™ – the First Oral Calcitonin for the Treatment of Postmenopausal Osteoporosis

7/14/2015 Enteris BioPharma Oral Formulation Progresses Into Phase 2 Study With Cara Therapeutics’ CR845

2/10/2015 Enteris BioPharma Launches Contract Manufacturing within 32,000 Square Foot, FDA inspected and cGMP Compliant Facility

     2014

12/09/2014 Enteris BioPharma’s Formulation Technology Enables Oral Delivery of Cara Therapeutics’ CR845 Peptide for Acute and Chronic Pain in Phase 1a / 1b Trial

06/20/2014 Enteris BioPharma Oral Peptide Delivery Technology Enables Key Clinical Milestone for Acute and Chronic Pain Drug

01/09/2014 Enteris BioPharma to Present at Biotech Showcase™ 2014

     2013

12/03/2013 Enteris BioPharma Forms Scientific Advisory Board to Enhance
Leadership in Oral Delivery of Peptide and Small Molecule Drugs

09/30/2013 Enteris BioPharma and Nordic BioScience’s KeyBioScience Enter Strategic Licensing Agreement to Develop Metabolic Peptides Using Enteris’ Proprietary Oral Drug Delivery and Manufacturing Platform

08/20/2013 Enteris BioPharma Appoints Timothy J. Saxon, Vice President of Business Development, to Expand “Peptelligence™ Partnering” Program

08/05/2013 Enteris BioPharma Initiates Business and Development Activities Targeting Oral Delivery of Peptides and Small Molecule Therapeutics